In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma

Histone deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitors (DNMTi) are in early clinical development for multiple myeloma (MM) therapy. Despite all encouraging pre-clinical data, clinical activity of HDACi and DNMTi is mostly lacking. To optimize the trials, characterization of the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2015-02, Vol.6 (5), p.3319-3334
Hauptverfasser:	Maes, Ken, De Smedt, Eva, Kassambara, Alboukadel, Hose, Dirk, Seckinger, Anja, Van Valckenborgh, Els, Menu, Eline, Klein, Bernard, Vanderkerken, Karin, Moreaux, Jérôme, De Bruyne, Elke
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - therapeutic use Azacitidine - analogs & derivatives Azacitidine - therapeutic use Biochemistry, Molecular Biology Cancer Cell Line, Tumor Computational Biology DNA (Cytosine-5-)-Methyltransferase 1 DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors DNA (Cytosine-5-)-Methyltransferases - metabolism DNA Methylation - drug effects Epigenesis, Genetic - drug effects Gene Expression Profiling - methods Gene Expression Regulation, Neoplastic - drug effects Genomics Hematology Histone Deacetylase Inhibitors - therapeutic use Human health and pathology Humans Hydroxamic Acids - therapeutic use Immunology Immunotherapy Life Sciences Mice, Inbred C57BL Molecular Targeted Therapy Multiple Myeloma - drug therapy Multiple Myeloma - enzymology Multiple Myeloma - genetics Multiple Myeloma - immunology Multiple Myeloma - mortality Pharmaceutical sciences Pharmacology Research Paper Transcription, Genetic - drug effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!